Biocept Stock

Biocept Current Assets

Delisted

The Current Assets of Biocept (BIOC) as of Sep 5, 2026 is 16.34 M USD. In the previous year, Current Assets was 45.69 M USD — a change of -64.23% (lower).

Current Assets

16.34 MUSD

YoY

-64.23%

Last updated:

Current Assets of Biocept is 2026 16.34 M USD. Current Assets of Biocept was 2025 45.69 M USD. It decreases by -64.23% lower compared to the previous year.

The Biocept Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2015
9.64 M USD
Jan 1, 2016
5.77 M USD
Jan 1, 2017
4.25 M USD
Jan 1, 2018
6.01 M USD
Jan 1, 2019
13.90 M USD
Jan 1, 2020
32.59 M USD
Jan 1, 2021
45.69 M USD
Jan 1, 2022
16.34 M USD
The Biocept Current Assets history
YEARCurrent AssetsYoY
16.34 MUSD-64.23%
45.69 MUSD+40.21%
32.59 MUSD+134.53%
13.90 MUSD+131.34%
6.01 MUSD+41.27%
4.25 MUSD-26.35%
5.77 MUSD-40.09%
9.64 MUSD+63.27%
5.90 MUSD+507.75%
971,132.00USD+68.31%
576,981.00USD-29.02%
812,902.00USD
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Current Assets of Biocept is 16.34 M USD in 2026.

Current Assets of Biocept changed from 45.69 M USD to 16.34 M USD, representing a -64.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Biocept since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Biocept historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Biocept

All Key Metrics — Biocept